Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Weinstock
Massachusetts Institute of Technology, Department: Engineering (All Types)
Should you be removed from our database? Contact us at [email protected]. Read more below.
Travera, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Travera, LLC is in the process of licensing from MIT the serial suspended microchannel resonator (SMR) technology developed by Scott Manalis. This research center grant aims to improve the prediction of drug efficacy using new strategies for predicting therapeutic response, which include use of the SMR. The Dana-Farber Cancer Institute Conflict of Interest Committee concluded that the results of this research could be of scientific and financial interest to Travera, LLC and, accordingly, represented a financial conflict of interest under the regulations.
Quantitative and functional characterization of therapeutic resistance in cancer
Overall Project Narrative Despite tremendous advances in our understanding of cancer pathogenesis, the treatment of individual patients with either conventional chemotherapy or targeted agents remains highly empiric. Better information about which treatment to offer an individual patient (i.e., precision medicine) could improve efficacy while sparing patients from the toxicity of therapies that offer no benefit. The overall goal of our U54 application is utilize new technology platforms for predicting therapeutic response in which phenotypic and genomic properties are measured at the single cell level. By pursuing this goal, our center will establish a framework that enables an iterative cycle between novel single-cell measurements from clinically-relevant specimens and computational approaches that result in testable predictions. Over the 5-year award, we plan to expand accessibility of these platforms to clinical studies across leukemias, colon and pancreatic cancers, and potentially a broader range of tumor types.
Filed on July 28, 2017.
Tell us what you know about David Weinstock's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “David Weinstock”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Weinstock | Dana Farber Cancer Inst | Conflict of Interest | Travera, LLC | Value cannot be readily determined |
| David Weinstock | Massachusetts Institute of Technology | Conflict of Interest | Travera, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.